External Skin Excision and Soft-Tissue Debulking for Nasal Tip Hypertrophy in Asians: An Implant-Free Approach

Nasal tip hypertrophy is common in Asians, and surgical refinement usually relies on tip grafts or structural implants. For patients who refuse any implant and whose bulbous tip is mainly caused by excessive soft tissue rather than cartilaginous deformity, available surgical options are limited. Herein, we introduce a new external nasal tip reduction procedure that removes redundant skin-superficial musculoaponeurotic system (SMAS)-fat tissue through a rhombus excision design to improve nasal tip contour without cartilage manipulation or implant placement.

A total of 13 patients with soft tissue-dominant nasal tip hypertrophy and refusal of implants were included in this study. All patients undergoing external skin excision and soft-tissue debulking were analyzed retrospectively. In this surgery, no grafts or implants were needed. Patient satisfaction and scar morphology were assessed at every follow-up visit.

All procedures were completed successfully, and nasal tip hypertrophy improved immediately after surgery. No infection, ischemia, or nasal tip collapse occurred. One patient developed mild hypertrophic scarring and underwent superficial scar removal surgery. All remaining patients showed inconspicuous scars. Five patients (5/13) reported being "very satisfied", 7 (7/13) reported being "satisfied", and 1 (1/13) being dissatisfied with nasal refinement and scar appearance. Follow-up ranged from 12 to 24 months, and no secondary implant-based revision was required. The procedure also produced slight nasal lengthening in patients with short noses.

This external nasal tip soft-tissue reduction technique provides an alternative option for Asian patients with nasal tip hypertrophy who refuse implants and have relatively small alar bases and thick nasal skin. With precise excision design and layered closure, visible scarring is minimal, and nasal tip contour can be refined safely and effectively. However, strict surgical indications must be respected.

Level IV-therapeutic study.